Advent Access is a medical technology startup focused on end-stage renal disease management. Founded on the principles of Stanford Biodesign and as a spin-off from A*STAR, Advent Access’ mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. Advent Access’ first product is the av-Guardian™ – an award-winning implant technology that aims to improve vascular access reliability, enable less-painful self-cannulation and in the long run, potentially reduce vascular access surgeries or hospitalizations. The av-GuardianTM forms a key component of Advent Access’ dialysis-machine agnostic platform to transform hemodialysis to be performed independently, safely and more affordably. Centered around the patient, the av-GuardianTM and the self-care platform seek to enable labour-light dialysis to be delivered in novel or alternative care environments.